
Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.

Your AI-Trained Oncology Knowledge Connection!


Instructor, Medicine, Harvard Medical School and an attending Physician, Medical Oncology, Dana-Farber Cancer Institute.

Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Benjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.